Definitive Healthcare Corp

Definitive Healthcare Corp. engages in the provision of healthcare commercial intelligence. Its solution offers information on healthcare providers and their activities to help the customers optimize from product development to go-to-market planning, sales, and marketing execution. The company was founded by Jason Kranzt in February 2011 and is headquartered in Framingham, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Definitive Healthcare reports robust Q4 performance amidst industry challenges

Definitive Healthcare's Q4 2022 performance reflects strong revenue growth and profitability, driven by strategic acquisitions and product innovations, despite economic headwinds.
Challenges such as extended deal cycles and macroeconomic impacts require adaptive strategies, while opportunities in data matching, client growth, and market expansion offer avenues for future success.
The company's focus on cost management, sales enhancements, and long-term growth in the healthcare data market positions it well for sustained performance and industry leadership.
Guidance for Q1 2023 underscores financial stability and growth potential, signaling a proactive approach to navigating challenges and seizing opportunities in the evolving healthcare landscape.

Definitive Healthcare Corp reports solid Q1 results amidst growth strategies

Definitive Healthcare Corp (DH) delivered solid Q1 results amidst challenges, with a focus on enhancing data capabilities and strategic M&A for future growth.
While facing higher churn and margin impacts, the company remains resilient, with stable pricing and a proactive approach to driving performance improvements.
Opportunities lie in acquisitions, cross-selling to existing clients, and maintaining a strong market position through innovation and client value creation.

Definitive Healthcare reports strong Q2 earnings, eyes AI opportunities

Definitive Healthcare's Q2 performance showcased revenue growth, EBITDA margin, and strategic acquisitions, despite workforce reductions and customer declines.
The company's strengths lie in tech investments, market share gains, and cross-sell opportunities, while challenges include workforce reductions and economic uncertainties.
Opportunities in AI advancements, long-term market prospects, and strategic investments position Definitive Healthcare for sustained growth and client value creation.

Definitive Healthcare Corp excels in Q3 amidst market challenges

Definitive Healthcare Corp's Q3 showcased strong financial performance, customer wins, and a focus on innovation despite market challenges.
The company's resilience, marketing effectiveness, and strategies to address churn position it well for future growth and success.
With a commitment to product development, customer engagement, and market leadership, Definitive Healthcare Corp navigates tough market conditions with adaptability.

Definitive Healthcare posts solid Q4 results, eyes growth opportunities in 2024

Definitive Healthcare's Q4 2023 performance was strong, with revenue growth, margin maintenance, and client base expansion.
The company's strategic focus on product investments, customer retention, and innovation positions it well for growth in 2024.
Challenges in the life sciences segment and high M&A valuations are being addressed through strategic initiatives and market positioning.
Opportunities in data asset investment, margin growth, and strong demand present avenues for continued success and expansion.

Definitive Healthcare reports mixed Q1 results, eyes growth opportunities

Definitive Healthcare's Q1 2024 Earnings Call showcased a resilient performance amidst challenges, with a focus on operational excellence and product innovation. Despite facing macroeconomic headwinds and restructuring disruptions, the company remains optimistic about long-term opportunities, driven by improving macro conditions and strategic initiatives.

Definitive Healthcare reports Q2 revenue growth, addresses sales challenges

Definitive Healthcare's Q2 2024 earnings call highlighted mixed performance, with a focus on addressing sales challenges and enhancing operational efficiency. CEO Coop emphasized growth, profitability, and strategic changes to drive shareholder value.

Definitive Healthcare reports Q3 results, plans for growth and efficiency

Definitive Healthcare's Q3 performance showed resilience despite revenue and EBITDA declines, with a strategic focus on simplification and customer success.
While facing challenges like high churn rates, the company aims for future growth through new product offerings and customer expansion.
Opportunities lie in operational efficiency improvements, share buyback program expansion, and strategic product integration for enhanced value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

First quarter revenue grew 36% year-over-year to $50.1 million First quarter revenue grew 36% year-over-year to $50.1 million

Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2022

Salesforce

Clearwater Analytics Holdings

ServiceNow

Paycom Software

Paylocity Hlds

Pubmatic

ZoomInfo Technologies

"Eventually, even these heinous stocks, formerly high-flying tech stocks, will get so cheap that they're going to find a bottom," the "Mad Money" host said.

Be ready to snatch up these 8 software stocks when they bottom, Jim Cramer says

FRAMINGHAM, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its first quarter ended March 31, 2022 financial results will be released on Thursday, May 5, 2022, after market close. The company will host a conference call and webcast at 4:30 PM (ET) / 1:30 PM (PT) to discuss the company's financial results.

Definitive Healthcare Announces Timing of Its First Quarter 2022 Financial Results Conference Call and Webcast

Expansive solution, built on Analytical Wizards technology, delivers data-agnostic analytics on-demand to life sciences customers Expansive solution, built on Analytical Wizards technology, delivers data-agnostic analytics on-demand to life sciences customers

Definitive Healthcare Launches Passport Analytics Suite

FRAMINGHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will present at two upcoming conferences: the Raymond James 43rd Annual Institutional Investors Conference in Orlando, Florida and the Deutsche Bank 30th Annual Media, Internet & Telecom Conference in Palm Beach, Florida.

Definitive Healthcare to Present at the Raymond James 43rd Annual Institutional Investors Conference and the Deutsche Bank 30th Annual Media, Internet & Telecom Conference

Definitive Healthcare Corp.'s (DH) CEO Jason Krantz on Q4 2021 Results - Earnings Call Transcript

Fourth quarter revenue grew 38% year-over-year to $46.3 million Full year 2021 revenue grew 40% to $166.2 million

Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Year Fiscal 2021

FRAMINGHAM, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its fourth quarter and full year ended December 31, 2021 financial results will be released on Wednesday, February 23, 2022, after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

Definitive Healthcare Announces Timing of Its Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast

By iteratively analyzing and reporting on real-world data, life sciences organizations can quickly assess multiple market opportunities during therapy development By iteratively analyzing and reporting on real-world data, life sciences organizations can quickly assess multiple market opportunities during therapy development

Definitive Healthcare launches Latitude Discovery for pre-commercial biopharma and medical device companies

FRAMINGHAM, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Founder and Chief Executive Officer, Jason Krantz, and its Chief Financial Officer, Rick Booth, will present at the Barclays Virtual Global Technology, Media and Telecommunications Conference.

Definitive Healthcare to Present at the Barclays Virtual Global Technology, Media and Telecommunications Conference

The company doesn't make drugs or devices -- which is part of the appeal.

Should You Put Your Next $1,000 Into This Healthcare IPO?

FRAMINGHAM, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced the closing of its previously announced underwritten public offering of 11,000,000 shares of its Class A common stock at a price to the public of $36.00 per share. The underwriters have a 30-day option to purchase up to an additional 1,650,000 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions.

Definitive Healthcare Announces Closing of Follow-On Offering of 11,000,000 Shares of Class A Common Stock

FRAMINGHAM, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced the pricing of an underwritten public offering of 11,000,000 shares of its Class A common stock at a price to the public of $36.00 per share. The underwriters have a 30-day option to purchase up to an additional 1,650,000 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions.

Definitive Healthcare Announces Pricing of Follow-On Offering of 11,000,000 Shares of Class A Common Stock

FRAMINGHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced the commencement of an underwritten public offering of 11,000,000 shares of its Class A common stock. In addition, Definitive Healthcare expects to grant the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions.

Definitive Healthcare Announces Launch of Proposed Follow-On Offering of 11,000,000 Shares of Class A Common Stock

Definitive Healthcare Corp.'s (DH) CEO Jason Krantz on Q3 2021 Results - Earnings Call Transcript

Third quarter revenue grew 43% year-over-year to $43.1 million Third quarter revenue grew 43% year-over-year to $43.1 million

Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2021

Life sciences companies can now access more than 11 million worldwide expert profiles to gain an even deeper understanding of Chinese and Japanese healthcare markets Life sciences companies can now access more than 11 million worldwide expert profiles to gain an even deeper understanding of Chinese and Japanese healthcare markets

Definitive Healthcare adds Asian expert data to Monocl ExpertInsight

FRAMINGHAM, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its third quarter ended September 30, 2021 financial results will be released on Monday, November 8, 2021, after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

Definitive Healthcare Announces Timing of Its Third Quarter 2021 Financial Results Conference Call and Webcast

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Definitive Healthcare Launches Latitude Reporting for Custom Patient Cohort Creation and Analytics

Definitive Healthcare Launches Latitude Reporting for Custom Patient Cohort Creation and Analytics

FRAMINGHAM, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that Robert Musslewhite has joined the company as President, a newly created role on the company's Executive Leadership Team.

Robert Musslewhite Joins Definitive Healthcare as President

Definitive Healthcare has seen a very successful public offering as investors like the role which it plays in a complex healthcare system. I like the role and prospects of the company and while it has good traction on the commercial side, valuations are far too high to be involved here.

Definitive Healthcare: Definitely Not For Me Here

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced the closing of its previously announced initial public offering of 17,888,888 shares of its Class A common stock, which includes the full exercise by the underwriters of their option to purchase up to an additional 2,333,333 shares of its Class A common stock, at a public offering price of $27.00 per share. Aggregate gr

News for Definitive Healthcare Corp Stock (DH)